Indiana University School of Medicine professor Jeff Dage, PhD’s research aided the Food and Drug Administration (FDA) clearance of Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio, according to a release.
Dr. Dage “helped lead the discovery and development of one of the biomarkers the test identifies.” He hopes it will help broaden the accessibility of Alzheimer's testing.
Dr. Dage and his collaborators used the test on a diverse group of patients and found “the test was 96% accurate in determining whether a patient had pathological evidence of disease — on par with FDA-cleared cerebrospinal fluid testing or PET scans.”
